Subtype
Neuroblastic Tumor
CI-CAN-00001274Explore in graph →
137 active trials3 approved drugs28 evidence items
- NCIt
- C6963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001274Explore in graph →
Clinical trials
619 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | completed | Phase 1 | 21 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01109238 |
| A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma |
| completed |
| — |
| 5 |
| Giselle ShollerOTHER |
| 1 |
| Aug 6, 2024 |
| clinicaltrials |
| NCT01355679 | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma | completed | N/A | 16 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01802567 | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | completed | N/A | 52 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | completed | Phase 2 | 140 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT05245123 | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families(PsyRareCare) | completed | — | 100 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03517280 | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil | completed | — | 17 | Columbia UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT02641314 | Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma(METRO-NB2012) | completed | Phase 2 | 18 | University of CologneOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT02169609 | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | completed | Phase 2 | 24 | Fundació Sant Joan de DéuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT06190574 | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma | completed | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02765243 | Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma(4SCAR-GD2) | completed | Phase 1 | 12 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03686566 | Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] | completed | — | 84 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT01526603 | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | completed | N/A | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04474678 | Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") | completed | N/A | 240 | Medical University of ViennaOTHER | 4 | Jan 9, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT02864563 | Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification(PHRCNB07) | completed | N/A | 560 | Institut CurieOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT02998983 | Racotumomab in Patients With High-risk Neuroblastoma | completed | Phase 2 | 39 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01728155 | European Low and Intermediate Risk Neuroblastoma Protocol | completed | Phase 3 | 685 | Instituto de Investigacion Sanitaria La FeOTHER | 10 | Sep 8, 2023 | clinicaltrials |
| NCT01419834 | Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors | completed | Phase 1 | 68 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL(CYCHEALL) | completed | Phase 1 | 32 | Baylor College of MedicineOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT00033293 | Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma | completed | Phase 3 | 53 | Children's Oncology GroupNETWORK | 3 | Apr 18, 2023 | clinicaltrials |
| NCT00005835 | N99-02: Melphalan and Buthionine Sulfoximine(BSO) | completed | Phase 1 | 31 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT00084422 | N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | completed | Phase 1 | 47 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT00885326 | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | completed | Phase 1 | 29 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 10, 2023 | clinicaltrials |
| NCT01019850 | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | completed | Phase 1 | 27 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02924324 | Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients | completed | N/A | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 5 | Oct 24, 2022 | clinicaltrials |
| NCT02035137 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat(N2011-01) | completed | Phase 2 | 114 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jun 8, 2022 | clinicaltrials |
| NCT00072358 | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | completed | Phase 2 | 291 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT00567567 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | completed | Phase 3 | 665 | Children's Oncology GroupNETWORK | 6 | Apr 28, 2022 | clinicaltrials |
| NCT00492167 | Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | completed | Phase 1 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | completed | Phase 1 | 25 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03042416 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | completed | Phase 3 | 400 | University of AlbertaOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03291080 | Oral Liquid 13-cis-retinoic Acid (13-CRA)(My-CRA) | completed | Phase 1 / Phase 2 | 20 | Nova Laboratories LimitedINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT00499616 | Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma | completed | Phase 3 | 464 | Children's Oncology GroupNETWORK | 6 | Jul 6, 2021 | clinicaltrials |
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2024source: clinicaltrials